Knee Osteoarthritis (Kellgren-Lawrence Grade 1-3)NCT07746466
Efficacy of Bioactive Collagen Peptide Compared to Glucosamine and Chondroitin Sulphate in Grade I-III Knee Osteoarthritis
A study testing Bioactive Collagen Peptide and Glucosamine and Chondroitin Sulphate in people with Knee Osteoarthritis (Kellgren-Lawrence Grade 1-3), run by Liaquat National Hospital & Medical College at 1 site in Pakistan.
Trial summary
Brief Summary The goal of this clinical trial is to learn whether bioactive collagen peptide works as well as glucosamine and chondroitin sulphate for improving pain, stiffness, physical function, and quality of life in adults with mild to moderate knee osteoarthritis (Kellgren-Lawrence grades I to III). Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Knee Osteoarthritis (Kellgren-Lawrence Grade 1-3)
- What is being tested?
- Bioactive Collagen Peptide and Glucosamine and Chondroitin Sulphate
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Jun 2023to 17 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 40 years and older.
- Clinical diagnosis of knee osteoarthritis according to the American College of Rheumatology (ACR) criteria.
- Radiographic Kellgren-Lawrence grade I, II, or III osteoarthritis in at least one knee.
- Willing and able to provide written informed consent.
- Willing to comply with the study protocol and attend all follow-up visits.
Who cannot join
- Inflammatory arthritis, including rheumatoid arthritis, systemic lupus erythematosus, spondyloarthropathy, or polymyalgia rheumatica.
- Post-traumatic osteoarthritis.
- Patients with hyperuricemia.
- Pregnancy or breastfeeding.
- Previous use of collagen peptide or glucosamine-chondroitin supplements before enrollment.
- Inability or unwillingness to comply with study procedures or complete follow-up.
Trial locations and contacts
1 site in 1 country.
Pakistan1 site
Liaquat National Hospital and Medical College
Karachi, Sindh, 74800
About this study
Official title: Efficacy of Bioactive Collagen Peptide Versus Glucosamine and Chondroitin Sulphate in Grade I-III Knee Osteoarthritis: A Randomized Controlled Trial
Brief Summary
The goal of this clinical trial is to learn whether bioactive collagen peptide works as well as glucosamine and chondroitin sulphate for improving pain, stiffness, physical function, and quality of life in adults with mild to moderate knee osteoarthritis (Kellgren-Lawrence grades I to III).
Read more
The main questions it aims to answer are:
Does bioactive collagen peptide improve knee pain, stiffness, and physical function over 12 weeks? Does bioactive collagen peptide improve health-related quality of life? Is bioactive collagen peptide as safe and effective as glucosamine and chondroitin sulphate for treating knee osteoarthritis?
Researchers will compare bioactive collagen peptide with glucosamine and chondroitin sulphate to determine whether one treatment provides greater improvement in symptoms and quality of life.
Participants will:
Be randomly assigned to receive either bioactive collagen peptide once daily or glucosamine and chondroitin sulphate twice daily for 12 weeks.
Attend study visits at the start of the study and again at 6 and 12 weeks. Complete questionnaires about their knee pain, stiffness, physical function, and overall health-related quality of life at each visit.
Be monitored for treatment adherence, use of rescue pain medication, and any side effects throughout the study.
The information from this study may help healthcare providers better understand whether bioactive collagen peptide is an effective and safe non-surgical treatment option for people with symptomatic knee osteoarthritis.
Read the detailed description
Knee osteoarthritis is one of the leading causes of chronic pain, disability, and reduced quality of life among adults. Current non-surgical management focuses primarily on symptom relief through exercise, weight management, physical therapy, and analgesic medications. Although non-steroidal anti-inflammatory drugs (NSAIDs) remain widely used, their long-term use may be limited by gastrointestinal, cardiovascular, and renal adverse effects. As a result, there is increasing interest in nutraceutical therapies that may provide symptomatic relief with a more favorable safety profile.
Glucosamine and chondroitin sulphate are among the most commonly used symptomatic slow-acting agents for osteoarthritis, although published evidence regarding their effectiveness remains inconsistent. Bioactive collagen peptides have emerged as a potential alternative treatment because they may support cartilage metabolism and reduce symptoms associated with osteoarthritis. However, direct comparative evidence between bioactive collagen peptides and glucosamine-chondroitin sulphate remains limited.
This study is a prospective, single-center, open-label, parallel-group randomized controlled trial designed to compare the efficacy and safety of oral bioactive collagen peptide with oral glucosamine and chondroitin sulphate in adults with symptomatic Kellgren-Lawrence grade I to III knee osteoarthritis.
Participants are randomly assigned in a 1:1 ratio to receive either oral bioactive collagen peptide or oral glucosamine and chondroitin sulphate for 12 weeks. Clinical assessments are performed at baseline, 6 weeks, and 12 weeks. The study evaluates changes in knee pain, stiffness, physical function, and health-related quality of life using validated patient-reported outcome measures, including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Safety is evaluated throughout the study by monitoring adverse events, medication compliance, and the use of rescue analgesics.
The primary objective is to determine whether bioactive collagen peptide provides clinical improvement comparable to glucosamine and chondroitin sulphate in reducing symptoms and improving function in patients with knee osteoarthritis. Secondary objectives include evaluating changes in health-related quality of life and comparing the safety and tolerability of both treatment strategies.
The findings of this study will provide comparative evidence regarding two commonly prescribed oral nutraceutical therapies for knee osteoarthritis and may help inform evidence-based conservative management of patients with early and moderate disease.
- Being tested
- Bioactive Collagen Peptide, Glucosamine and Chondroitin Sulphate
- Keywords
- Knee osteoarthritis, collagen peptides, glucosamine, chondroitin sulphate, WOMAC index, EQ-5D-5L, quality of life, nutraceuticals, symptomatic slow-acting drugs for osteoarthritis, randomized controlled trial, RCT
- Medical subject headings
- Osteoarthritis, Knee
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bioactive Collagen PeptideDietary supplement
Also called Collagen Peptide, Hydrolyzed Fish Collagen Peptide
Participants assigned to this intervention receive oral bioactive collagen peptide (Movgen®), containing fish collagen 4,000 mg and Curcuma longa extract 250 mg. The supplement is administered orally at a dose of 8 g once daily for 12 weeks as conservative treatment for symptomatic Kellgren-Lawrence grade I-III knee osteoarthritis.
Glucosamine and Chondroitin SulphateDietary supplement
Also called Glucosamine Sulphate, Chondroitin Sulphate, Glucosamine-Chondroitin Combination
Participants assigned to this intervention receive an oral combination of glucosamine sulphate and chondroitin sulphate (Gebon Plus®), containing glucosamine sulphate 400 mg, chondroitin sulphate 300 mg, methylsulfonylmethane 200 mg, hyaluronic acid 100 mg, Boswellia serrata extract 40 mg, Smilax chinensis extract 30 mg, and Curcuma longa extract 30 mg. The supplement is administered orally twice daily for 12 weeks as conservative treatment for symptomatic Kellgren-Lawrence grade I-III knee osteoarthritis.
| Study group | Role | What they receive |
|---|---|---|
| Bioactive Collagen Peptide (Movgen®) | Experimental | Oral bioactive collagen peptide Fish collagen 4000 mg + Curcuma longa extract 250 mg Dose: 8 g once daily Duration: 12 weeks Receives: Dietary Supplement: Bioactive Collagen Peptide |
| Glucosamine and Chondroitin Sulphate (Gebon Plus®) | Active comparator | Glucosamine sulphate 400 mg Chondroitin sulphate 300 mg Methylsulfonylmethane 200 mg Hyaluronic acid 100 mg Boswellia serrata extract 40 mg Smilax chinensis extract 30 mg Curcuma longa extract 30 mg Dose: Twice daily Duration: 12 weeks Receives: Dietary Supplement: Glucosamine and Chondroitin Sulphate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score
Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score from baseline to 12 weeks. The WOMAC total score ranges from 0 to 96, with lower scores indicating less pain, stiffness, and physical disability and therefore better clinical outcomes. The questionnaire includes three domains: pain, stiffness, and physical function.
Measured: From baseline to 6 weeks and from 6 weeks to 12 weeks (Total 3 months)
Change in Health-Related Quality of Life (EQ-5D-5L)
Change in health-related quality of life measured using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire from baseline to 12 weeks. Outcomes include the EQ-5D-5L Index, which ranges from less than 0 (health states considered worse than death) to 1.0 (full health), with higher scores indicating better health-related quality of life, and the EQ Visual Analogue Scale (EQ VAS), which ranges from 0 to 100, where higher scores indicate better perceived overall health.
Measured: From baseline to 6 weeks and from 6 weeks to 12 weeks (Total 12 weeks/3months)
Secondary outcomes (1)
Incidence of Adverse Events
Number and type of treatment-related adverse events reported during the 12-week study period, including treatment discontinuation due to adverse effects.
Measured: Throughout the 12-week treatment period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2026
- Study start1 Jun 2023
- Primary completion15 Aug 2025
- Study completion17 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Knee Osteoarthritis (Kellgren-Lawrence Grade 1-3)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Liaquat National Hospital & Medical College
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sumaiya Khan, Liaquat National Hospital & Medical College
- Investigators
- Sumaiya Khan, MBBS, MRCS(Ire), FCPS, Principal investigator, Liaquat National Hospital and Medical College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07746466
- Sponsor's protocol ID
- RC-LNH-Ortho-05/2023/52
- Status last verified
- Aug 2026
- First submitted
- 28 Jul 2026
- Last updated
- 10 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Individual participant data (IPD) that underlie the results reported in publications, after de-identification, will be made available to qualified researchers upon reasonable request. Requests will be reviewed by the principal investigator, and data may be shared for scientifically sound research purposes following approval of a data sharing agreement and in accordance with institutional policies and applicable ethical and regulatory requirements. No personally identifiable participant information will be shared.
Publications
Trc T, Bohmova J. Efficacy and tolerance of enzymatic hydrolysed collagen (EHC) vs. glucosamine sulphate (GS) in the treatment of knee osteoarthritis (KOA). Int Orthop. 2011 Mar;35(3):341-8. doi: 10.1007/s00264-010-1010-z. Epub 2010 Apr 19.
PubMed 20401752Knapik JJ, Pope R, Hoedebecke SS, Schram B, Orr R, Lieberman HR. Effects of Oral Glucosamine Sulfate on Osteoarthritis-Related Pain and Joint-Space Changes: Systematic Review and Meta-Analysis. J Spec Oper Med. 2018 Winter;18(4):139-147. doi: 10.55460/AUC0-QM7H.
PubMed 30566740Simental-Mendia M, Sanchez-Garcia A, Vilchez-Cavazos F, Acosta-Olivo CA, Pena-Martinez VM, Simental-Mendia LE. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. Rheumatol Int. 2018 Aug;38(8):1413-1428. doi: 10.1007/s00296-018-4077-2. Epub 2018 Jun 11.
PubMed 29947998Benito-Ruiz P, Camacho-Zambrano MM, Carrillo-Arcentales JN, Mestanza-Peralta MA, Vallejo-Flores CA, Vargas-Lopez SV, Villacis-Tamayo RA, Zurita-Gavilanes LA. A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort. Int J Food Sci Nutr. 2009;60 Suppl 2:99-113. doi: 10.1080/09637480802498820. Epub 2009 Feb 11.
PubMed 19212858Bruyere O, Zegels B, Leonori L, Rabenda V, Janssen A, Bourges C, Reginster JY. Effect of collagen hydrolysate in articular pain: a 6-month randomized, double-blind, placebo controlled study. Complement Ther Med. 2012 Jun;20(3):124-30. doi: 10.1016/j.ctim.2011.12.007. Epub 2012 Jan 20.
PubMed 22500661Van Vijven JP, Luijsterburg PA, Verhagen AP, van Osch GJ, Kloppenburg M, Bierma-Zeinstra SM. Symptomatic and chondroprotective treatment with collagen derivatives in osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2012 Aug;20(8):809-21. doi: 10.1016/j.joca.2012.04.008. Epub 2012 Apr 17.
PubMed 22521757
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Bioactive Collagen Peptide Versus Glucosamine and Chondroitin Sulphate in Grade I-III Knee Osteoarthritis: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07746466
- Acronym / sponsor ID
- RC-LNH-Ortho-05/2023/52
- Keywords
- Knee osteoarthritis, collagen peptides, glucosamine, chondroitin sulphate, WOMAC index, EQ-5D-5L, quality of life, nutraceuticals
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Liaquat National Hospital & Medical CollegeUniversity, hospital or other
- Study start
- 1 Jun 2023 (actual)
- Primary completion
- 15 Aug 2025 (actual)
- Study completion
- 17 Aug 2025 (actual)
- First posted
- 5 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Brief Summary
The goal of this clinical trial is to learn whether bioactive collagen peptide works as well as glucosamine and chondroitin sulphate for improving pain, stiffness, physical function, and quality of life in adults with mild to moderate knee osteoarthritis (Kellgren-Lawrence grades I to III).
The main questions it aims to answer are:
Does bioactive collagen peptide improve knee pain, stiffness, and physical function over 12 weeks? Does bioactive collagen peptide improve health-related quality of life? Is bioactive collagen peptide as safe and effective as glucosamine and chondroitin sulphate for treating knee osteoarthritis?
Researchers will compare bioactive collagen peptide with glucosamine and chondroitin sulphate to determine whether one treatment provides greater improvement in symptoms and quality of life.
Participants will:
Be randomly assigned to receive either bioactive collagen peptide once daily or glucosamine and chondroitin sulphate twice daily for 12 weeks.
Attend study visits at the start of the study and again at 6 and 12 weeks. Complete questionnaires about their knee pain, stiffness, physical function, and overall health-related quality of life at each visit.
Be monitored for treatment adherence, use of rescue pain medication, and any side effects throughout the study.
The information from this study may help healthcare providers better understand whether bioactive collagen peptide is an effective and safe non-surgical treatment option for people with symptomatic knee osteoarthritis.
Detailed description
Knee osteoarthritis is one of the leading causes of chronic pain, disability, and reduced quality of life among adults. Current non-surgical management focuses primarily on symptom relief through exercise, weight management, physical therapy, and analgesic medications. Although non-steroidal anti-inflammatory drugs (NSAIDs) remain widely used, their long-term use may be limited by gastrointestinal, cardiovascular, and renal adverse effects. As a result, there is increasing interest in nutraceutical therapies that may provide symptomatic relief with a more favorable safety profile.
Glucosamine and chondroitin sulphate are among the most commonly used symptomatic slow-acting agents for osteoarthritis, although published evidence regarding their effectiveness remains inconsistent. Bioactive collagen peptides have emerged as a potential alternative treatment because they may support cartilage metabolism and reduce symptoms associated with osteoarthritis. However, direct comparative evidence between bioactive collagen peptides and glucosamine-chondroitin sulphate remains limited.
This study is a prospective, single-center, open-label, parallel-group randomized controlled trial designed to compare the efficacy and safety of oral bioactive collagen peptide with oral glucosamine and chondroitin sulphate in adults with symptomatic Kellgren-Lawrence grade I to III knee osteoarthritis.
Participants are randomly assigned in a 1:1 ratio to receive either oral bioactive collagen peptide or oral glucosamine and chondroitin sulphate for 12 weeks. Clinical assessments are performed at baseline, 6 weeks, and 12 weeks. The study evaluates changes in knee pain, stiffness, physical function, and health-related quality of life using validated patient-reported outcome measures, including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Safety is evaluated throughout the study by monitoring adverse events, medication compliance, and the use of rescue analgesics.
The primary objective is to determine whether bioactive collagen peptide provides clinical improvement comparable to glucosamine and chondroitin sulphate in reducing symptoms and improving function in patients with knee osteoarthritis. Secondary objectives include evaluating changes in health-related quality of life and comparing the safety and tolerability of both treatment strategies.
The findings of this study will provide comparative evidence regarding two commonly prescribed oral nutraceutical therapies for knee osteoarthritis and may help inform evidence-based conservative management of patients with early and moderate disease.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Bioactive Collagen Peptide (Movgen®) | Experimental | Dietary Supplement: Bioactive Collagen PeptideOral bioactive collagen peptide Fish collagen 4000 mg + Curcuma longa extract 250 mg Dose: 8 g once daily Duration: 12 weeks |
| Glucosamine and Chondroitin Sulphate (Gebon Plus®) | Active comparator | Dietary Supplement: Glucosamine and Chondroitin SulphateGlucosamine sulphate 400 mg Chondroitin sulphate 300 mg Methylsulfonylmethane 200 mg Hyaluronic acid 100 mg Boswellia serrata extract 40 mg Smilax chinensis extract 30 mg Curcuma longa extract 30 mg Dose: Twice daily Duration: 12 weeks |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adults aged 40 years and older.
- Clinical diagnosis of knee osteoarthritis according to the American College of Rheumatology (ACR) criteria.
- Radiographic Kellgren-Lawrence grade I, II, or III osteoarthritis in at least one knee.
- Willing and able to provide written informed consent.
- Willing to comply with the study protocol and attend all follow-up visits.
Key exclusion criteria (6 listed)
- Inflammatory arthritis, including rheumatoid arthritis, systemic lupus erythematosus, spondyloarthropathy, or polymyalgia rheumatica.
- Post-traumatic osteoarthritis.
- Patients with hyperuricemia.
- Pregnancy or breastfeeding.
- Previous use of collagen peptide or glucosamine-chondroitin supplements before enrollment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bioactive Collagen PeptideAlso: Collagen Peptide, Hydrolyzed Fish Collagen PeptideParticipants assigned to this intervention receive oral bioactive collagen peptide (Movgen®), containing fish collagen 4,000 mg and Curcuma longa extract 250 mg. The supplement is administered orally at a dose of 8 g once daily for 12 weeks as conservative treatment for symptomatic Kellgren-Lawrence grade I-III knee osteoarthritis. | Dietary supplement | Bioactive Collagen Peptide (Movgen®) |
| Glucosamine and Chondroitin SulphateAlso: Glucosamine Sulphate, Chondroitin Sulphate, Glucosamine-Chondroitin CombinationParticipants assigned to this intervention receive an oral combination of glucosamine sulphate and chondroitin sulphate (Gebon Plus®), containing glucosamine sulphate 400 mg, chondroitin sulphate 300 mg, methylsulfonylmethane 200 mg, hyaluronic acid 100 mg, Boswellia serrata extract 40 mg, Smilax chinensis extract 30 mg, and Curcuma longa extract 30 mg. The supplement is administered orally twice daily for 12 weeks as conservative treatment for symptomatic Kellgren-Lawrence grade I-III knee osteoarthritis. | Dietary supplement | Glucosamine and Chondroitin Sulphate (Gebon Plus®) |
Primary outcome
Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score
Time frame: From baseline to 6 weeks and from 6 weeks to 12 weeks (Total 3 months)
Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score from baseline to 12 weeks. The WOMAC total score ranges from 0 to 96, with lower scores indicating less pain, stiffness, and physical disability and therefore better clinical outcomes. The questionnaire includes three domains: pain, stiffness, and physical function.
Change in Health-Related Quality of Life (EQ-5D-5L)
Time frame: From baseline to 6 weeks and from 6 weeks to 12 weeks (Total 12 weeks/3months)
Change in health-related quality of life measured using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire from baseline to 12 weeks. Outcomes include the EQ-5D-5L Index, which ranges from less than 0 (health states considered worse than death) to 1.0 (full health), with higher scores indicating better health-related quality of life, and the EQ Visual Analogue Scale (EQ VAS), which ranges from 0 to 100, where higher scores indicate better perceived overall health.
1 secondary outcome
Incidence of Adverse Events
Time frame: Throughout the 12-week treatment period
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2026.
- Background: PubMed 20401752Trc T, Bohmova J. Efficacy and tolerance of enzymatic hydrolysed collagen (EHC) vs. glucosamine sulphate (GS) in the treatment of knee osteoarthritis (KOA). Int Orthop. 2011 Mar;35(3):341-8. doi: 10.1007/s00264-010-1010-z. Epub 2010 Apr 19.
- Background: PubMed 30566740Knapik JJ, Pope R, Hoedebecke SS, Schram B, Orr R, Lieberman HR. Effects of Oral Glucosamine Sulfate on Osteoarthritis-Related Pain and Joint-Space Changes: Systematic Review and Meta-Analysis. J Spec Oper Med. 2018 Winter;18(4):139-147. doi: 10.55460/AUC0-QM7H.
- Background: PubMed 29947998Simental-Mendia M, Sanchez-Garcia A, Vilchez-Cavazos F, Acosta-Olivo CA, Pena-Martinez VM, Simental-Mendia LE. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. Rheumatol Int. 2018 Aug;38(8):1413-1428. doi: 10.1007/s00296-018-4077-2. Epub 2018 Jun 11.
- Background: PubMed 19212858Benito-Ruiz P, Camacho-Zambrano MM, Carrillo-Arcentales JN, Mestanza-Peralta MA, Vallejo-Flores CA, Vargas-Lopez SV, Villacis-Tamayo RA, Zurita-Gavilanes LA. A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort. Int J Food Sci Nutr. 2009;60 Suppl 2:99-113. doi: 10.1080/09637480802498820. Epub 2009 Feb 11.
- Background: PubMed 22500661Bruyere O, Zegels B, Leonori L, Rabenda V, Janssen A, Bourges C, Reginster JY. Effect of collagen hydrolysate in articular pain: a 6-month randomized, double-blind, placebo controlled study. Complement Ther Med. 2012 Jun;20(3):124-30. doi: 10.1016/j.ctim.2011.12.007. Epub 2012 Jan 20.
- Background: PubMed 22521757Van Vijven JP, Luijsterburg PA, Verhagen AP, van Osch GJ, Kloppenburg M, Bierma-Zeinstra SM. Symptomatic and chondroprotective treatment with collagen derivatives in osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2012 Aug;20(8):809-21. doi: 10.1016/j.joca.2012.04.008. Epub 2012 Apr 17.
- Individual participant dataSharing planned: Undecided. Individual participant data (IPD) that underlie the results reported in publications, after de-identification, will be made available to qualified researchers upon reasonable request. Requests will be reviewed by the principal investigator, and data may be shared for scientifically sound research purposes following approval of a data sharing agreement and in accordance with institutional policies and applicable ethical and regulatory requirements. No personally identifiable participant information will be shared.
Related trials for Knee Osteoarthritis (Kellgren-Lawrence Grade 1-3)
Active, not recruiting
Targeted Rehabilitation Versus Standard Care in Managing Medial Knee Pain and Varus Malalignment: A Randomized Control Trial
Knee Osteoarthritis (Kellgren-Lawrence Grade 1-3)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sumaiya Khan, MBBS, MRCS(Ire), FCPS principal investigator
Liaquat National Hospital and Medical College
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bioactive Collagen Peptide and Glucosamine and Chondroitin Sulphate in people with Knee Osteoarthritis (Kellgren-Lawrence Grade 1-3), run by Liaquat National Hospital & Medical College at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Total Score (time frame: From baseline to 6 weeks and from 6 weeks to 12 weeks (Total 3 months)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07746466, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2026.